The Filings Report

BridgeBio Pharma, Inc. Common Stock

BBIONasdaqCIK 1743881Healthcare / Drug Manufacturersfiscal year ends December33 quarters since 2018

Revenue, Q3 FY2026
$353M
+192.6% on Q3 FY2025
Net income
−$57M
+69.0% on Q3 FY2025
Free cash flow
−$44M
+59.6% on Q3 FY2025
Diluted EPS
$-0.42
+55.8% on Q3 FY2025
Revenue, TTM
$946M
trailing four quarters
Net margin, TTM
-59.8%
net income −$566M
Free cash flow, TTM
−$370M
−$369M less $835K capex
Cash and equivalents
$1.5B
long-term debt $2.6B, Sep 30, 2026
Shares, 12-month change
+1.1%
195M shares, Sep 30, 2026
Buybacks, TTM
$253M
1.7% of market value
Dividends, TTM
—
no yield
Market value
$14.6B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, BridgeBio Pharma, Inc. Common Stock reported revenue of $353M, +192.6% on Q3 FY2025, and net loss of $57M (+69.0%). Net income this quarter is driven by non-operating items: −$48M of other income against −$12M of operating income, so it reflects gains or losses outside the operations. Operating margin was −3.3%. Free cash flow, operating cash flow less capital expenditures, was −$44M (−$44M less $290K). Diluted earnings per share were $-0.42.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$400M−$200M$0$200M$400MQ4'22, Revenue: $2MQ4'22, Net income: −$138MQ4'22Q1'23, Revenue: $2MQ1'23, Net income: −$140MQ1'23Q2'23, Revenue: $2MQ2'23, Net income: −$158MQ2'23Q3'23, Revenue: $4MQ3'23, Net income: −$177MQ3'23Q4'23, Revenue: $2MQ4'23, Net income: −$168MQ4'23Q1'24, Revenue: $211MQ1'24, Net income: −$35MQ1'24Q2'24, Revenue: $2MQ2'24, Net income: −$73MQ2'24Q3'24, Revenue: $3MQ3'24, Net income: −$162MQ3'24Q4'24, Revenue: $6MQ4'24, Net income: −$265MQ4'24Q1'25, Revenue: $117MQ1'25, Net income: −$167MQ1'25Q2'25, Revenue: $111MQ2'25, Net income: −$182MQ2'25Q3'25, Revenue: $121MQ3'25, Net income: −$183MQ3'25Q4'25, Revenue: $154MQ4'25, Net income: −$193MQ4'25Q1'26, Revenue: $195MQ1'26, Net income: −$164MQ1'26Q2'26, Revenue: $244MQ2'26, Net income: −$152MQ2'26Q3'26, Revenue: $353MQ3'26, Net income: −$57MQ3'26−$400M−$200M$0$200M$400MQ4'22, Revenue: $2MQ4'22, Net income: −$138MQ1'23, Revenue: $2MQ1'23, Net income: −$140MQ1'23Q2'23, Revenue: $2MQ2'23, Net income: −$158MQ3'23, Revenue: $4MQ3'23, Net income: −$177MQ3'23Q4'23, Revenue: $2MQ4'23, Net income: −$168MQ1'24, Revenue: $211MQ1'24, Net income: −$35MQ1'24Q2'24, Revenue: $2MQ2'24, Net income: −$73MQ3'24, Revenue: $3MQ3'24, Net income: −$162MQ3'24Q4'24, Revenue: $6MQ4'24, Net income: −$265MQ1'25, Revenue: $117MQ1'25, Net income: −$167MQ1'25Q2'25, Revenue: $111MQ2'25, Net income: −$182MQ3'25, Revenue: $121MQ3'25, Net income: −$183MQ3'25Q4'25, Revenue: $154MQ4'25, Net income: −$193MQ1'26, Revenue: $195MQ1'26, Net income: −$164MQ1'26Q2'26, Revenue: $244MQ2'26, Net income: −$152MQ3'26, Revenue: $353MQ3'26, Net income: −$57MQ3'26

Net income losses drawn in red.

Free cash flow
−$300M−$200M−$100M$0$100MQ4'22, Free cash flow: −$94MQ4'22Q1'23, Free cash flow: −$144MQ1'23Q2'23, Free cash flow: −$114MQ2'23Q3'23, Free cash flow: −$146MQ3'23Q4'23, Free cash flow: −$125MQ4'23Q1'24, Free cash flow: −$220MQ1'24Q2'24, Free cash flow: $75MQ2'24Q3'24, Free cash flow: −$181MQ3'24Q4'24, Free cash flow: −$195MQ4'24Q1'25, Free cash flow: −$199MQ1'25Q2'25, Free cash flow: −$81MQ2'25Q3'25, Free cash flow: −$110MQ3'25Q4'25, Free cash flow: −$56MQ4'25Q1'26, Free cash flow: −$197MQ1'26Q2'26, Free cash flow: −$72MQ2'26Q3'26, Free cash flow: −$44MQ3'26−$300M−$200M−$100M$0$100MQ4'22, Free cash flow: −$94MQ1'23, Free cash flow: −$144MQ1'23Q2'23, Free cash flow: −$114MQ3'23, Free cash flow: −$146MQ3'23Q4'23, Free cash flow: −$125MQ1'24, Free cash flow: −$220MQ1'24Q2'24, Free cash flow: $75MQ3'24, Free cash flow: −$181MQ3'24Q4'24, Free cash flow: −$195MQ1'25, Free cash flow: −$199MQ1'25Q2'25, Free cash flow: −$81MQ3'25, Free cash flow: −$110MQ3'25Q4'25, Free cash flow: −$56MQ1'26, Free cash flow: −$197MQ1'26Q2'26, Free cash flow: −$72MQ3'26, Free cash flow: −$44MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3BQ4'22, Cash and equivalents: $377MQ4'22, Long-term debt: $431MQ4'22Q1'23, Cash and equivalents: $407MQ1'23, Long-term debt: $436MQ1'23Q2'23, Cash and equivalents: $302MQ2'23, Long-term debt: $440MQ2'23Q3'23, Cash and equivalents: $505MQ3'23, Long-term debt: $442MQ3'23Q4'23, Cash and equivalents: $376MQ4'23, Long-term debt: $446MQ4'23Q1'24, Cash and equivalents: $475MQ1'24, Long-term debt: $435MQ1'24Q2'24, Cash and equivalents: $408MQ2'24, Long-term debt: $435MQ2'24Q3'24, Cash and equivalents: $266MQ3'24, Long-term debt: $436MQ3'24Q4'24, Cash and equivalents: $681MQ4'24, Long-term debt: $437MQ4'24Q1'25, Cash and equivalents: $541MQ1'25, Long-term debt: $0Q1'25Q2'25, Cash and equivalents: $749MQ2'25, Long-term debt: $0Q2'25Q3'25, Cash and equivalents: $643MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $570MQ4'25, Long-term debt: $2.0BQ4'25Q1'26, Cash and equivalents: $880MQ1'26, Long-term debt: $2.7BQ1'26Q2'26, Cash and equivalents: $678MQ2'26, Long-term debt: $2.7BQ2'26Q3'26, Cash and equivalents: $1.5BQ3'26, Long-term debt: $2.6BQ3'26$0$1B$2B$3BQ4'22, Cash and equivalents: $377MQ4'22, Long-term debt: $431MQ1'23, Cash and equivalents: $407MQ1'23, Long-term debt: $436MQ1'23Q2'23, Cash and equivalents: $302MQ2'23, Long-term debt: $440MQ3'23, Cash and equivalents: $505MQ3'23, Long-term debt: $442MQ3'23Q4'23, Cash and equivalents: $376MQ4'23, Long-term debt: $446MQ1'24, Cash and equivalents: $475MQ1'24, Long-term debt: $435MQ1'24Q2'24, Cash and equivalents: $408MQ2'24, Long-term debt: $435MQ3'24, Cash and equivalents: $266MQ3'24, Long-term debt: $436MQ3'24Q4'24, Cash and equivalents: $681MQ4'24, Long-term debt: $437MQ1'25, Cash and equivalents: $541MQ1'25, Long-term debt: $0Q1'25Q2'25, Cash and equivalents: $749MQ2'25, Long-term debt: $0Q3'25, Cash and equivalents: $643MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $570MQ4'25, Long-term debt: $2.0BQ1'26, Cash and equivalents: $880MQ1'26, Long-term debt: $2.7BQ1'26Q2'26, Cash and equivalents: $678MQ2'26, Long-term debt: $2.7BQ3'26, Cash and equivalents: $1.5BQ3'26, Long-term debt: $2.6BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

BridgeBio Pharma, Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 10, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue3532441951541211111176+192.6%
Cost of revenue20151087432+211.6%
Gross profit—————————
Research and development144149127116113111111130+27.1%
Selling, general and administrative20118616415813812910695+45.9%
Operating income(12)(107)(106)(140)(145)(134)(104)(226)+92.0%
Other income (expense)(48)(49)(61)(55)(41)(47)(65)(40)−15.4%
Pretax income(59)(156)—(195)(186)(182)—(266)+68.2%
Income tax10—0(2)201+179.5%
Net income(57)(152)(164)(193)(183)(182)(167)(265)+69.0%
Diluted EPS ($)(0.42)(0.78)(0.84)—(0.95)(0.95)(0.88)—+55.8%
Diluted shares (millions)196196195—192191190——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

BridgeBio Pharma, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 10, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents1,533678880570643749541681+138.5%
Short-term investments542601738—0+83.6%
Total current assets2,0451,0931,241798839912695721+143.6%
Total assets2,1621,2171,3719369981,080882919+116.6%
Total current liabilities977891816288217176152154+351.2%
Long-term debt2,6302,6532,6532,0072,00700437+31.0%
Total liabilities3,8153,7233,6403,0132,9212,8592,5202,377+30.6%
Stockholders’ equity(1,662)(2,515)(2,278)(2,087)(1,933)(1,788)(1,648)(1,468)+14.0%
Shares outstanding (millions)195195196194193191190190—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

BridgeBio Pharma, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 10, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(44)(71)(197)(56)(110)(81)(199)(195)+59.7%
Capital expenditures00000100−38.3%
Free cash flow (CFO − capex)(44)(72)(197)(56)(110)(81)(199)(195)+59.6%
Depreciation and amortization11111111−23.5%
Share repurchases4212883000480—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

BridgeBio Pharma, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Mar 3, 2020FY2018ended Dec 31, 2018filed Aug 14, 2019FY2017ended Dec 31, 2017filed Nov 8, 2019
Revenue50222297870841——
Cost of revenue214233————
Gross profit—————————
Research and development45250645639945133721014031
Selling, general and administrative531289151143192146944413
Operating income(523)(593)(607)(512)(577)(474)(266)(184)(44)
Other income (expense)(209)51(46)28(10)(31)(22)140
Pretax income(733)(542)(653)(485)—50528916944
Income tax0100—————
Net income(725)(536)(643)(481)(563)(449)(261)(131)(31)
Diluted EPS ($)(3.78)(2.88)(3.95)(3.26)(3.90)(3.80)———
Diluted shares (millions)192186163147144118———

Balance sheet

BridgeBio Pharma, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Mar 3, 2020FY2018ended Dec 31, 2018filed Aug 14, 2019FY2017ended Dec 31, 2017filed Nov 8, 2019
Cash and equivalents57068137637739435636443692
Short-term investments170052394251182——
Total current assets798721478549889643569445—
Total assets9369195466231,013704632465—
Total current liabilities288154144121135966033—
Long-term debt2,007437446431431929255—
Total liabilities3,0132,3771,8891,8681,87859615688—
Stockholders’ equity(2,087)(1,468)(1,354)(1,255)(870)5840831586
Shares outstanding (millions)194190176151148149124——

Cash flow statement

BridgeBio Pharma, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Mar 3, 2020FY2018ended Dec 31, 2018filed Aug 14, 2019FY2017ended Dec 31, 2017filed Nov 8, 2019
Operating cash flow(446)(521)(528)(419)(498)(400)(254)(137)(40)
Capital expenditures1115138320
Free cash flow (CFO − capex)(447)(522)(529)(424)(511)(407)(256)(139)(41)
Depreciation and amortization5667611——
Share repurchases4800020075———
Dividends paid——————1—1

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
10 sales by 2 insiders; officers and directors $5M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$105M
154 sales by 9 insiders; officers and directors $105M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 30, 2026Apuli MaricelChief Accounting Officeropen-market sale10b5-12,000$72.85$146K120,687Nov 3, 2026
Sep 17, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-1indirect8,721$69.01$602K496,965Sep 21, 2026
Sep 17, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-1indirect1,279$69.57$89K495,686Sep 21, 2026
Aug 19, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-1indirect8,100$83.86$679K507,586Aug 20, 2026
Aug 19, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-1indirect1,800$84.69$152K505,786Aug 20, 2026
Aug 19, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-1indirect100$85.65$9K505,686Aug 20, 2026
Aug 18, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-11,900$81.15$154K276,407Aug 20, 2026
Aug 18, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-117,279$82.21$1M259,128Aug 20, 2026
Aug 18, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-114,602$82.99$1M244,526Aug 20, 2026
Aug 18, 2026Kumar NeilChief Executive Officer, Directoropen-market sale10b5-11,199$83.77$100K243,327Aug 20, 2026
Aug 16, 2026Trimarchi ThomasPresident and CFOtax withholding22,781$79.86$2M336,529Aug 18, 2026
Aug 16, 2026Kumar NeilChief Executive Officer, Directoroption exercise33,544——276,871Aug 18, 2026
Aug 16, 2026Kumar NeilChief Executive Officer, Directoroption exercise19,599——296,470Aug 18, 2026
Aug 16, 2026Kumar NeilChief Executive Officer, Directoroption exercise11,554——308,024Aug 18, 2026
Aug 16, 2026Kumar NeilChief Executive Officer, Directoroption exercise6,520——314,544Aug 18, 2026
Aug 16, 2026Kumar NeilChief Executive Officer, Directortax withholding36,237$79.86$3M278,307Aug 18, 2026
Aug 16, 2026Apuli MaricelChief Accounting Officertax withholding4,714$79.86$376K122,687Aug 18, 2026
Jul 30, 2026Apuli MaricelChief Accounting Officeropen-market sale10b5-12,000$80.06$160K127,401Aug 3, 2026
Jul 9, 2026Ellis AndreaDirectoroption exercise17,167$16.75$288K39,746Jul 13, 2026
Jul 9, 2026Ellis AndreaDirectoropen-market sale10b5-117,167$84.00$1M22,579Jul 13, 2026
Jul 9, 2026Cook Jennifer E.Directoroption exercise19,000$8.45$161K27,383Jul 13, 2026
Jul 9, 2026Cook Jennifer E.Directoroption exercise112,422$29.00$3M139,805Jul 13, 2026
Jul 9, 2026Cook Jennifer E.Directoroption exercise17,167$16.75$288K156,972Jul 13, 2026
Jul 9, 2026Cook Jennifer E.Directoropen-market sale10b5-136,167$84.00$3M120,805Jul 13, 2026
Jul 9, 2026Cook Jennifer E.Directoropen-market sale10b5-1112,422$90.00$10M8,383Jul 13, 2026

Full insider history for BridgeBio Pharma, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BridgeBio Pharma, Inc., CIK 1743881 on EDGAR
Extract generated
November 4, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2021
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss, NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/BBIO.json